Gene-silencing therapies may finally be able to reach hard-to-target organs like the brain and kidney by hitching a ride on the body’s own delivery vesicles, which naturally home to specific cell types and can deliver RNA drugs at far lower, safer doses.
ACCESS Health International
The potential to deactivate the genetic causes of severe diseases is becoming increasingly achievable, provided these therapies can effectively target the necessary cells. While delivering gene-silencing drugs to cells in controlled laboratory settings is relatively straightforward, doing so within the human body presents more challenges.
These drugs must navigate the bloodstream, evade immune defenses, and penetrate only the intended cell types, avoiding others. Often, they fail, accumulating in the liver and leaving patients with diseases originating in other organs without effective treatment. A new method proposes a promising solution: utilizing the body’s own delivery systems.
The Delivery Problem
Gene-silencing therapies utilize short RNA strands to intercept and destroy the molecular instructions for producing harmful proteins. Regulatory agencies have already approved several such drugs, but most are effective only in the liver. This is because the liver is easily accessible and absorbs particles from the bloodstream, making it the default destination for most injected therapies.
Reaching other organs is more challenging, often requiring higher doses, which increase the risk of toxicity and immune reactions. The brain, in particular, is difficult to access due to a tightly regulated barrier preventing most circulating molecules from entering. Consequently, a gap remains between what is effective in vitro and what works in vivo, posing a significant challenge in modern genetic medicine.
Nature’s Targeting System
However, the body already has a solution to a similar problem. Cells continuously release small membrane-bound bubbles known as extracellular vesicles, or exosomes, which carry proteins and RNA between cells, acting as a natural communication network.
While most conventional drugs function like bulk shipping, circulating widely with much of the “cargo” ending up in central hubs like the liver, exosomes operate more like a personalized courier service. They have built-in address labels guiding them to specific cell types, ensuring the package not only reaches the right neighborhood but also enters the correct house, where the therapeutic payload can be utilized.
These vesicles are not arbitrary messengers; they carry built-in targeting signals that direct them to specific cell types. This presents a compelling possibility: instead of engineering synthetic delivery systems, naturally occurring vesicles that already “know” their destination can be harnessed.
This concept was tested by collecting vesicles from different cell types, tracking their movement through the body, and evaluating whether they successfully delivered their cargo to target cells. This is crucial because while many delivery systems can reach an organ, far fewer can enter the right cells and release their payload.
Reaching the Brain
In testing brain delivery, vesicles were injected into the cerebrospinal fluid surrounding the brain and spinal cord in mice with a gene linked to dementia. Vesicles from specific brain-related cell types reduced the target gene’s expression by approximately 50% to 80% across multiple brain regions, including areas typically hard to reach. Vesicles from other sources, such as commonly used lab cells, showed little to no effect. In monkeys, the same method achieved up to 80% gene silencing in outer brain regions and 60% in deeper memory-related structures, with the treatment spreading well beyond the injection site, without causing inflammation or behavioral changes.
Reaching the Kidneys
For targeting kidneys, vesicles from young skin cells proved particularly effective. These vesicles traveled through the bloodstream and localized in the kidney’s filtering units, the precise site where certain disease-causing genes are active. In a mouse model of kidney disease, the treatment reduced target gene activity by up to 90% and decreased protein leakage into urine by more than 85%, significantly improving the kidney’s structural damage. In a second model, gene silencing reversed scarring to near-normal levels. In rabbits, the same strategy achieved over 70% gene silencing in the kidney, suggesting this approach can be scaled effectively.
These vesicles naturally target specific cells and deliver their contents efficiently, requiring much less drug. Conventional kidney delivery approaches can require doses up to 50 times those used for liver-targeted therapies. The vesicle-based system achieved equal or better results with about one-fiftieth the amount. At these lower doses, no significant toxicity, immune reactions, or organ damage was observed in the models.
What Comes Next
The results are currently preclinical, demonstrated in mice, rabbits, and a limited number of monkeys. Further research is needed to scale production, confirm durability, and establish safety in larger studies before human trials can begin. Nonetheless, the implications are substantial.
If naturally derived vesicles can reliably deliver gene therapies to specific cell types, they could usher in a new era in medicine, characterized by precise biological targeting.
